P95's Strategic Acquisition: Enhancing Clinical Research Services
P95 BV, a well-respected name in epidemiology and clinical solutions, has made a significant move by acquiring Assign DMB, a reputable clinical research organization. This acquisition is a crucial milestone for P95, which is known for its strong emphasis on vaccines and infectious diseases. It allows them to broaden their capabilities and strengthen their global presence in data management and biostatistics.
The Legacy of Assign DMB
Founded in 2005 by the visionary Anton Klinger, Assign DMB has earned a solid reputation in Austria for its specialization in clinical data management and biometrics. Their dedication to quality has established them as a reliable partner for numerous clinical studies, particularly in the fields of infectious diseases and vaccine research. Through this acquisition, P95 is set to leverage Assign DMB's expertise, thereby enhancing its overall service offerings.
Integrating Expertise for Greater Impact
Thomas Verstraeten, the CEO of P95, expressed his excitement about welcoming Anton and his skilled team. He noted that this collaboration will enhance P95's ability to conduct both clinical and non-interventional studies, reinforcing their mission to support vaccine and infectious disease research on a global scale. The combined strengths of both companies will improve their capacity to deliver high-quality services worldwide, including in developing regions.
What This Means for P95's Future
The acquisition of Assign DMB signifies more than just a strategic enhancement; it underscores P95's commitment to driving innovation in clinical research. The amalgamation of their experiences and resources allows them to meet the intricate demands of modern clinical trials more effectively. With regional hubs spanning Africa, Latin America, North America, and Southeast Asia, P95 is continuously expanding its global reach.
A Broader Range of Services
P95 now provides a comprehensive array of full-service CRO solutions across five continents. Their offerings encompass clinical trials from Phase I-IV, epidemiological studies, real-world evidence, vaccine development consulting, and much more. This extensive range positions P95 as an industry leader, adept at addressing diverse client needs.
About P95: A Leader in Epidemiology and Clinical Solutions
Based in Belgium, P95 has emerged as a leading global provider of clinical solutions. Their focus on vaccines and infectious diseases reflects their commitment to enhancing public health. With a dedicated team of around 300 professionals, they have experience operating in over 30 countries, delivering high-quality services tailored to the specific demands of clinical research.
The Significance of Ampersand Capital Partners
Ampersand Capital Partners plays a vital role in facilitating P95's growth and innovation strategies. With $3 billion in assets under management, Ampersand is well-known for its dedication to the healthcare sector. Their partnership with P95 strengthens the latter's ability to drive performance and achieve sustainable growth in clinical research.
Frequently Asked Questions
1. What led to the acquisition of Assign DMB by P95?
P95 aimed to enhance its data management and biostatistics services, enabling them to deliver higher quality clinical research globally.
2. Who is the CEO of Assign DMB?
Anton Klinger, the founder, and current CEO of Assign DMB, will continue to lead the team under the P95 umbrella.
3. How will this acquisition benefit P95's services?
This acquisition will expand P95's capacity to conduct various studies more efficiently while enhancing their focus on vaccines and infectious diseases.
4. What types of services does P95 offer?
P95 provides a wide range of services including clinical trials, epidemiology studies, vaccine consulting, data management, and biostatistics.
5. Where is P95 headquartered?
P95 is headquartered in Belgium, with regional offices strategically located across several continents to support global operations.
